<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152620</url>
  </required_header>
  <id_info>
    <org_study_id>13171B</org_study_id>
    <nct_id>NCT00152620</nct_id>
  </id_info>
  <brief_title>Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease</brief_title>
  <official_title>Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <brief_summary>
    <textblock>
      The aim of this therapeutic trial is to compare the response of subjects with active IBD to
      daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study completed
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Crohn's Disease Activity Index (PCDAI)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical-Activity Index for the Evaluation of Patients with Ulcerative Colitis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Harvey Bradshaw score (pHB)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Inflammatory Bowel Disease (IBD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parental informed consent

          -  Subjects 6 to 19 years of age with confirmed diagnosis of IBD (Crohn's disease,
             ulcerative colitis or indeterminate colitis), who on admission to the hospital have a
             PCDAI&gt;15 or a Clinical-Activity Index for the Evaluation of Patients with Ulcerative
             Colitis of &gt;10.

          -  Infectious causes (viruses, bacteria, parasites) have been ruled out.

        Exclusion Criteria:

          -  Subjects in which the administration of corticosteroids would be contraindicated such
             as systemic or enteric infections diagnosed by stool analysis including culture,
             Clostridium Difficile toxin assay, rotavirus or adenovirus 40/41 antigens.

          -  Subjects with enterostomy or colostomy

          -  Subjects with one or more of the following conditions: unstable vital signs, acute
             abdomen, toxic megacolon, intestinal obstruction, intestinal perforation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara S Kirschner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>EDWARDS FC, TRUELOVE SC. THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS. Gut. 1964 Feb;5:1-22.</citation>
    <PMID>14127503</PMID>
  </reference>
  <reference>
    <citation>Truelove SC. The management of ulcerative colitis. Br J Clin Pract. 1974 Jan;28(1):5-10.</citation>
    <PMID>4149894</PMID>
  </reference>
  <reference>
    <citation>Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol. 1991 Jul-Aug;9(4):413-23. Review.</citation>
    <PMID>1934694</PMID>
  </reference>
  <reference>
    <citation>Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993 Dec;14(12):436-41. Review.</citation>
    <PMID>7510080</PMID>
  </reference>
  <reference>
    <citation>Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis. 1998 Aug;4(3):177-81.</citation>
    <PMID>9741018</PMID>
  </reference>
  <reference>
    <citation>Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974 Jun 1;1(7866):1067-70.</citation>
    <PMID>4135487</PMID>
  </reference>
  <reference>
    <citation>Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun;28(2):297-321. Review.</citation>
    <PMID>10372270</PMID>
  </reference>
  <reference>
    <citation>Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 1987 Feb;9(1):50-4.</citation>
    <PMID>3031150</PMID>
  </reference>
  <reference>
    <citation>Kaplan HP, Portnoy B, Binder HJ, Amatruda T, Spiro H. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology. 1975 Jul;69(1):91-5.</citation>
    <PMID>168121</PMID>
  </reference>
  <reference>
    <citation>Panés J, Esteve M, Cabré E, Hinojosa J, Andreu M, Sans M, Fernandez-Bañares F, Feu F, Gassull MA, Piqué JM. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000 Oct;119(4):903-8.</citation>
    <PMID>11040177</PMID>
  </reference>
  <reference>
    <citation>Sood A, Midha V, Sood N, Awasthi G. A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis. J Clin Gastroenterol. 2002 Oct;35(4):328-31.</citation>
    <PMID>12352296</PMID>
  </reference>
  <reference>
    <citation>Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003 Nov;43(11):1216-27.</citation>
    <PMID>14551176</PMID>
  </reference>
  <reference>
    <citation>Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut. 2002 May;50 Suppl 3:III43-6. Review.</citation>
    <PMID>11953332</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease (IBD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

